Research programme: neuropeptide FF receptor antagonists - Juvantia Pharma

Drug Profile

Research programme: neuropeptide FF receptor antagonists - Juvantia Pharma

Alternative Names: Neuropeptide FF receptor antagonists research programme - Juvantia Pharma

Latest Information Update: 16 Feb 2009

Price : $50

At a glance

  • Originator Juvantia Pharma
  • Class
  • Mechanism of Action Neuropeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 20 Jul 2005 This programme is still in active development - (BIO-2005)
  • 19 Jan 2001 Preclinical development for Pain in Finland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top